MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412283 | Name: Capreomycin IA

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Capreomycin IA is an antibiotic which is given in combination with other antibiotics for the treatment of tuberculosis. Specifically it is a second line treatment used for active drug resistant tuberculosis. It is given by injection into a vein or muscle.

Chemical Structure

Capreomycin IA
Capreomycin IA
CAS#37280-35-6

Theoretical Analysis

MedKoo Cat#: 412283

Name: Capreomycin IA

CAS#: 37280-35-6

Chemical Formula: C25H44N14O8

Exact Mass: 668.3467

Molecular Weight: 668.72

Elemental Analysis: C, 44.90; H, 6.63; N, 29.32; O, 19.14

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Capreomycin IA; A250-II; A 250-II; A-250-II; Capstat; Antibiotic 29275; Antibiotic A-250-II;
IUPAC/Chemical Name
(S)-3,6-diamino-N-(((2S,5S,11S,15S,Z)-15-amino-2-(hydroxymethyl)-11-((R)-2-iminohexahydropyrimidin-4-yl)-3,6,9,12,16-pentaoxo-8-(ureidomethylene)-1,4,7,10,13-pentaazacyclohexadecan-5-yl)methyl)hexanamide
InChi Key
JNIIDKODPGHQSS-MPSMQSNBSA-N
InChi Code
InChI=1S/C25H44N14O8/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47)/b15-9-/t11-,12-,13+,14-,16-,18-/m0/s1
SMILES Code
NCCC[C@@H](CC(NC[C@@H]1NC([C@@H](NC([C@H](CNC([C@H]([C@H]2CCNC(N2)=N)NC(/C(NC1=O)=C/NC(N)=O)=O)=O)N)=O)CO)=O)=O)N
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Common side effects include kidney problems, hearing problems, poor balance, and pain at the site of injection. Other side effects include paralysis resulting in the inability to breathe. It is not recommended with streptomycin or other medications that may damage the auditory vestibular nerve. It is not recommended during pregnancy as it may cause kidney or hearing problems in the baby. Capreomycin is commonly grouped with the aminoglycoside family of medications. How it works is unclear. Capreomycin was discovered from Streptomyces capreolus in 1960. It was removed from the World Health Organization's List of Essential Medicines in 2019.

Preparing Stock Solutions

The following data is based on the product molecular weight 668.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Liu G, Luan B, Liang G, Xing L, Huang L, Wang C, Xu Y. Isolation and identification of four major impurities in capreomycin sulfate. J Chromatogr A. 2018 Oct 12;1571:155-164. doi: 10.1016/j.chroma.2018.08.015. Epub 2018 Aug 7. PMID: 30115387. 2: Thuboy B, Kellermann T, Castel S, Norman J, Joubert A, Garcia-Prats AJ, Hesseling AC, Wiesner L. The determination of capreomycin in human plasma by LC- MS/MS using ion-pairing chromatography and solid-phase extraction. Biomed Chromatogr. 2018 May 3:e4269. doi: 10.1002/bmc.4269. Epub ahead of print. PMID: 29726023. 3: Martin A, Paasch F, Docx S, Fissette K, Imperiale B, Ribón W, González LA, Werngren J, Engström A, Skenders G, Juréen P, Hoffner S, Del Portillo P, Morcillo N, Palomino JC. Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug- resistant (XDR) Mycobacterium tuberculosis. J Antimicrob Chemother. 2011 Apr;66(4):827-33. doi: 10.1093/jac/dkq527. Epub 2011 Jan 19. PMID: 21393176. 4: Thiara AS, Cundliffe E. Analysis of two capreomycin-resistance determinants from Streptomyces capreolus and characterization of the action of their products. Gene. 1995 Dec 29;167(1-2):121-6. doi: 10.1016/0378-1119(95)00702-4. PMID: 8566762. 5: Nomoto S, Teshima T, Wakamiya T, Shiba T. The revised structure of capreomycin. J Antibiot (Tokyo). 1977 Nov;30(11):955-9. doi: 10.7164/antibiotics.30.955. PMID: 73540. 6: Shiba T, Nomoto S, Wakamiya T. The chemical structure of capreomycin. Experientia. 1976 Sep 15;32(9):1109-11. doi: 10.1007/BF01927571. PMID: 61134.